Share this article on:

A Systematic Analysis of the Off-label use of Bevacizumab For Severe Retinopathy of Prematurity: Erratum.

Evidence-Based Ophthalmology: July 2010 - Volume 11 - Issue 3 - p 175
doi: 10.1097/IEB.0b013e3181e8f834

The article that appeared on page 112 of the April 2010 issue had an author missing from the author list as well as missing and incorrect author affiliations.

The correct author list and affiliations are as follows:

Andrew B. Merkur, MD, FRCSC*

Khaled A. Tawansy, MD†

David A. Albiani, MD, FRCSC*

Shahrukh N. Bakar, BSc (Hon.)‡

*Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

†Children's Retina Institute, Los Angeles, CA

‡School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada

Back to Top | Article Outline


1. Merkur AB, Tawansy KA, Albiani DA. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Evid Based Ophthalmol. 2010;11:112–114.
    © 2010 Lippincott Williams & Wilkins, Inc.